Loading...
•
Sep 30, 2022
TherapeuticsMD Q3 2022 Earnings Report
TherapeuticsMD's Q3 2022 financial results were announced, with a total revenue of $20.9 million and a reduction in operating expenses by $22 million year-over-year.
Key Takeaways
TherapeuticsMD reported a decrease in net revenues by $4.5 million compared to the prior year, but reduced operating expenses by $22 million year-over-year. The company's wholesale network is now fully stocked, and operations have stabilized after a cash infusion from Rubric Capital.
Total revenue for Q3 2022 was $20.9 million.
ANNOVERA TRx grew by 10% year-over-year.
Operating expenses were reduced by $22 million year-over-year.
The company's wholesale network is now fully stocked, and operations have stabilized after a cash infusion from Rubric Capital.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...